{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urethritis-male/prescribing-information/metronidazole/","result":{"pageContext":{"chapter":{"id":"f4c18a1e-b367-5433-ac91-efd9bce81a5e","slug":"metronidazole","fullItemName":"Metronidazole","depth":2,"htmlHeader":"<!-- begin field 3d681980-a520-4912-94a1-afcf3f1b9e4b --><h2>Metronidazole</h2><!-- end field 3d681980-a520-4912-94a1-afcf3f1b9e4b -->","summary":"","htmlStringContent":"<!-- begin item 5643b43b-c6bf-4843-913e-9e50e5fffac2 --><!-- end item 5643b43b-c6bf-4843-913e-9e50e5fffac2 -->","topic":{"id":"f36465a1-1338-5604-8bb2-c8e555c598ae","topicId":"9d634e3c-7474-4d96-bbcb-7c29c10c1b03","topicName":"Urethritis - male","slug":"urethritis-male","lastRevised":"Last revised in September 2019","chapters":[{"id":"ac50911c-3aae-5117-95ce-67557d49723a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ae05a825-47bf-5fc0-9065-c859d8427b3b","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1c94ea5f-b73f-51a3-9d99-83814d055e3f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8e3d5f57-add8-5b6f-bd13-9ea05bc5ec30","slug":"changes","fullItemName":"Changes"},{"id":"7353c5be-d0ed-506f-8487-265ce270e97f","slug":"update","fullItemName":"Update"}]},{"id":"644de86f-bfeb-5ebf-8cda-c1be15f8938a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bd23c29c-af09-54b6-be4e-9f6ed812d62a","slug":"goals","fullItemName":"Goals"},{"id":"63346f4c-c71f-5887-b6d3-0d07661b1393","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"49121260-b8cb-5ecc-855a-f87303bc727e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"40b6a387-e841-594d-8616-fb4e8f4391e1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7d3a51c9-f614-5196-8052-55ceb4b6cf08","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b2b68ef0-16c8-5dbc-b8f8-fbdfa673ed3f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"027c2bf3-1625-560c-902b-9fef54935849","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"95898c97-d200-5648-b696-7388ab850318","slug":"definition","fullItemName":"Definition"},{"id":"9b0e6aa9-b665-52de-bfa3-93f09f83bc3d","slug":"causes","fullItemName":"Causes"},{"id":"f9c36294-6c74-5b9e-8afb-65b38bfa14e1","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2d0fc428-15ca-543a-bd93-b4ac231ed0cb","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"b7be062a-0eff-5e83-9493-809927e4776a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"60b1f452-fec4-567e-b8f0-39660841e61b","slug":"when-to-suspect-urethritis","fullItemName":"When to suspect urethritis"},{"id":"d5d984a2-a3d7-533a-9b94-02ac51c4fa07","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"75471ada-cb93-59f3-97b0-3c182e9f80b7","fullItemName":"Management","slug":"management","subChapters":[{"id":"b6607a10-84f2-51a2-ac03-a68ccb8dcbe9","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"513fcd9d-25a9-5183-98b5-32bdef8e6d5a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6598b6d1-3e66-518c-9a8b-63eff17fecaf","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"c498c9de-1083-50a6-b290-ac30aebda851","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"ecf258dc-1499-5f7a-a781-6566ea1a4f54","slug":"ofloxacin","fullItemName":"Ofloxacin"},{"id":"f4c18a1e-b367-5433-ac91-efd9bce81a5e","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"221c9f46-f915-5e6f-8275-959420090646","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"25917416-1fc8-5919-9773-f3b7e054b6a0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2ad44d6a-7cb1-598d-9dd4-9552f4f7fb49","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"791a5ccc-3882-5e9e-a55e-fc18bff5d67a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7370a44f-6a25-58d8-a772-568023fd6516","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"991288b5-d1b7-50f9-8e87-ceaf3331e0e2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"bf8f6743-57dd-5f6e-9460-bbecad8fd0b5","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b2d086b7-cf3d-5d24-994a-e0280f2397db","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"513fcd9d-25a9-5183-98b5-32bdef8e6d5a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"42f8b1d6-8fb8-5181-bb23-14d68f506535","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 79b9ab05-4503-48b3-be43-4c8846e5c50e --><h3>Contraindications and cautions</h3><!-- end field 79b9ab05-4503-48b3-be43-4c8846e5c50e -->","summary":"","htmlStringContent":"<!-- begin item afd73d23-9091-43b6-8e3d-da14d200dc0b --><!-- begin field 43ee549e-e20d-4b5c-8084-5401b90d06a1 --><ul><li><strong>Do not prescribe metronidazole to a person with:</strong><ul><li>Known metronidazole or nitroimidazole hypersensitivity.</li><li>Cockayne syndrome. Cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use (oral and suppositories). For people with Cockayne syndrome specialist advice should therefore be sought before prescribing metronidazole. </li></ul></li><li><strong>Prescribe metronidazole with caution </strong><strong>to people with:</strong><ul><li>Active or chronic severe peripheral and central nervous system disease, as there is a risk of neurological aggravation.</li><li>Severe liver disease or hepatic encephalopathy, due to substantial impairment of metronidazole clearance, which may contribute to symptoms of encephalopathy. Prescribe one-third of the daily dosage once daily.</li><li>Alcohol dependency — there may be a disulfiram-like reaction (flushing, increased respiratory rate, increased pulse rate, nausea, headache, and dizziness) if taken with alcohol.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 43ee549e-e20d-4b5c-8084-5401b90d06a1 --><!-- end item afd73d23-9091-43b6-8e3d-da14d200dc0b -->","subChapters":[]},{"id":"7e492ef4-3ae0-5abb-8b6d-c4b86aa31a23","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field c494bfe8-5b30-45c2-a0d5-a87d5a9837e4 --><h3>Adverse effects</h3><!-- end field c494bfe8-5b30-45c2-a0d5-a87d5a9837e4 -->","summary":"","htmlStringContent":"<!-- begin item 69339e81-58fb-4dcb-8358-1dbd8acc9fca --><!-- begin field f20d0bf7-5b93-4e3f-aacd-b1721d515804 --><ul><li><strong>Adverse effects of metronidazole include:</strong><ul><li>Gastro-intestinal disturbances (including nausea and vomiting), taste disturbances, furred tongue, oral mucositis, anorexia; very rarely hepatitis, jaundice, pancreatitis, drowsiness, dizziness, headache, ataxia, psychotic disorders, darkening of urine, thrombocytopenia, pancytopenia, myalgia, arthralgia, visual disturbances, rash, pruritis, and erythema multiforme.</li><li>Drowsiness, dizziness, confusion, hallucinations, convulsions or transient visual disorders — advise the person not to drive or operate machinery if these symptoms occur.</li><li>Severe bullous skin reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or acute generalised exanthematous pustulosis (AGEP). If symptoms/signs are present, treatment must be immediately discontinued.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field f20d0bf7-5b93-4e3f-aacd-b1721d515804 --><!-- end item 69339e81-58fb-4dcb-8358-1dbd8acc9fca -->","subChapters":[]},{"id":"10768c57-83d3-5a57-9f54-16c98265b217","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 30ae76a4-512c-48aa-9843-dca69553d546 --><h3>Drug interactions</h3><!-- end field 30ae76a4-512c-48aa-9843-dca69553d546 -->","summary":"","htmlStringContent":"<!-- begin item 746d3c85-837d-42fb-9b75-6135013d9707 --><!-- begin field 0850c803-c2a9-42bb-b1e5-4da7a3c48ac1 --><p><strong>Important drug interactions associated with metronidazole include:</strong></p><ul><li><strong>Alcohol </strong>— some people taking oral metronidazole may experience a disulfiram-like reaction with alcohol (flushing, increased respiratory rate, increased pulse rate, nausea, headache, and dizziness).</li><li><strong>Anticoagulants </strong>— the anticoagulant effects of warfarin can be markedly increased by metronidazole.<ul><li>Monitor the international normalized ratio (INR) if metronidazole is given with warfarin and adjust the warfarin dose accordingly.</li><li>Warn the person of the possible risk of increased bruising and bleeding. Advise when to seek medical help.</li></ul></li><li><strong>Ciclosporin </strong>— the Summary of Product Characteristics (SPC) states that when co-administration of metronidazole and ciclosporin are necessary serum ciclosporin and serum creatinine should be closely monitored.</li><li><strong>Lithium </strong>— seek expert advice regarding the concurrent use of metronidazole and lithium as lithium dose adjustments may be required. Plasma concentrations of lithium, creatinine and electrolytes should be monitored in people being treated with lithium while receiving metronidazole.</li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urethritis-male/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 0850c803-c2a9-42bb-b1e5-4da7a3c48ac1 --><!-- end item 746d3c85-837d-42fb-9b75-6135013d9707 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}